Skip to main content
. 2020 May 28;106(7):1968–1978. doi: 10.3324/haematol.2019.223529

Figure 3.

Figure 3.

AZD1208 inhibits platelet aggregation. (A-E, i and ii) Washed human platelets were pretreated with increasing concentrations of AZD1208 (0.1, 1, 10 μM) prior to stimulation with (A) collagen (1 μg/mL), (B) CRP-XL (0.3 μg/mL), (C) U46619 (0.3 μM), (D) thrombin (0.03 U/mL) or (E) ADP (10 μM) and aggregation monitored using optical light transmission aggregometry. (i) Representative traces and (ii) quantified data are shown. (A-E, iii) Human washed platelets were pretreated with 10 μM AZD1208 (red) or vehicle (black) prior to stimulation with (A) collagen (0.01-10 μg/mL), (B) CRP-XL (1-3 μg/mL), (C) U46619 (3 nM - 3 μM), (D) thrombin (0.01-1 U/mL) or (E) ADP (0.1-100 μM) and aggregation was monitored after 5 min using an optical light transmission plate-based aggregometry assay; quantified data are shown. Results are mean ± standard error mean for n≥3, *P≤0.05 ***P≤0.005 in comparison to vehicle control; where normalized data are shown statistics were performed prior to normalization.